Increased carboplatin concentration in liver tumors through temporary flow retardation with starch microspheres (Spherex) and gelatin powder (Gelfoam): An experimental study in liver tumor-bearing rabbits

Journal of Surgical Research

Volumn 92, Issue 2, 2000, Pages 165-170

  Pohlen, U ^a   Berger, G ^a   Binnenhei, M ^a   Reszka, R ^b   Buhr, H J ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Carboplatin; Chemoembolization; Chemotherapy; Gelatin powder; Starch microspheres

Indexed keywords

CARBOPLATIN; GELFOAM; STARCH MICROSPHERE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ARTIFICIAL EMBOLISM; COLORECTAL CANCER; CYTOSTASIS; DRUG BLOOD LEVEL; LIVER METASTASIS; LIVER TUMOR; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; TUMOR GROWTH;

EID: 0033863139     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.2000.5856     Document Type: Article

References (42)

1. Regional delivery of microspheres to liver metastases: The effects of particle size and concentration on hepatic distribution
2. Periodicity in metastasic tumor growth demonstrated in the human liver at autopsy
3. Treatment of unresectable primary liver cancer with intrahepatic fluorodeoxyuridine and mitomycin C through an implantable pump
4. Biodegradable cross-linked albumin microcapsules for embolization
5. Blood supply to hepatic V2 carcinoma implants as measured by radioactive microspheses
6. The blood supply of neoplasms in the liver
7. Manipulation of regional drug delivery in an animal model of colorectal metastases using degradable starch microspheres and angiotensin II
8. Liver and tumor uptake and plasma pharmacokinetic of arterial cisplatin administered with and without starch microspheres in patients with liver metastases
9. Segmental MTX and 5-FU: Advance or myth?
10. Pharmacologic rationale for regional drug delivery
11. Pharmacokinetics of mitomycin C following hepatic arterial chemoembolization with Gelfoam
12. Rationale for the use of starch as a vascular occlusive agent
13. Pharmacokinetics of carboplatin after i.v. administration
14. Hepatic arterial chemotherapy for primary and metastatic liver cancers
15. Multivariate analysis of a personal of 247 consecutive patients with liver metastases from colorectal cancer. I. Treatment by hepatic resection
16. Preparation and evaluation of two formulations: Cisplatin suspension in Lipiodol and polyactic acid microspheres containing aclarubicin hydrochloride: For intrahepatic arterial administration therapy for hepatocellular carcinoma
17. Vascular patterns in human metastatic liver tumors
18. Direct analysis of platinum in plasma and urine by electrothermal atomic absorption spectrophotometry
19. Experimental study on effective regional chemotherapy to liver cancer. Region
20. Resection of the liver for colorectal metastases: A multiinstitutional study of long term survival
21. Regional treatment of hepatic metastases and hepatocellular carcinoma
22. Transcatheter hepatic arterial chemoembolization using epirubicin- lipiodol: Experimental and pharmacological evaluation
23. Clinical Pharmacokinetics: A Short Introduction. Berlin/Heidelberg/New York: Springer-Verlag
24. A study of embolizing materials for chemo-embolization therapy of hepatocellular carcinoma: Antitumor effect of cis- diamminedichloroplatinum(II) albumin microspheres, containing chitin and treated with chitosan on rabbits with VX2 hepatic tumors. Chem. Pharm. Bull
25. Doxorubicin for unresectable hepatocellular carcinoma: A prospective study on the addition of verapamil
26. The blood supply of experimental liver metastases. II. A microvasculatory study of the normal and tumor vessels of the liver with the use of perfused silicone rubber
27. Plasma pharmacokinetics, urinary excretion and tissue distribution of platinum following IV administration of cyclobutandicarboxylatoplatinum-II and cis-platinum to rabbits
28. Treatment of hepatic cancer by hepatic arterial infusion chemotherapy
29. Epidemiology of hepatocellular carcinoma. In K. Okuda, and K. Ishak (Eds.), Neoplasms of the Liver. Tokyo: Springer Verlag
30. Estimates of the worldwide frequency of twelve major cancers. Bull
31. Chemoembolization of hepatocellular carcinomas
32. The emerging role for biomodulation of anti-neoplastic agents
33. Comparative distribution and excretion of carboplatin and cisplatin in mice
34. Chemoembolization of primary and metastatic liver tumors
35. A comparative randomized study on the treatment of primary and secondary liver tumours with intra-arterial chemotherapy with or without degradable starch microspheres (DSM)[Spherex®]
36. WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: A molecular approach
37. Clinical pharmacokinetics of carboplatin
38. Carboplatin: A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer
39. Treatment of primary liver cancer: Response with regional chemotherapy
40. Liver parenchymal changes after transcatheter arterial embolization therapy for hepatoma: CT-evaluation
41. Combination chemoembolization therapy for hepatocellular carcinoma: Mainly, using cisplatin (CDDP)
42. Phase II trial if high dose recombinant gamma-interferon in advanced hepatocellular and unknown primary neoplasms in the liver